CD166 Regulates Human and Murine Hematopoietic Stem Cell Function and the Hematopoietic Niche
CD166 Regulates Human and Murine Hematopoietic Stem Cell Function and the Hematopoietic Niche
批准号:
10544547
负责人:
Melissa A Kacena
金额:
$35.44万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-02-01 至 2024-12-31
关键词:
ALCAM geneActivities of Daily LivingBiologyCell CommunicationCell surfaceCellsClassificationCompetenceCytokine SignalingDataDefectENG geneElementsEndosteumEndothelial CellsEngraftmentEpigenetic ProcessGenesGenetic ModelsHematological DiseaseHematopoiesisHematopoieticHematopoietic SystemHematopoietic stem cellsHumanImmobilizationImmunoglobulinsIncubatedInvestigationKnockout MiceLigandsMaintenanceMarrowMediatingMesenchymal Stem CellsMitochondriaMusOsteoblastsPECAM1 genePTPRC genePathway interactionsPhenotypePlatelet-Derived Growth Factor alpha ReceptorPlayProteinsPublishingRegulationResearchResearch PersonnelRoleSLAM proteinSignal PathwayStem cell pluripotencySurfaceTestingTimeTranslational ResearchTreesWild Type Mouseblood treatmentcell typefitnesshematopoietic stem cell nichehematopoietic stem cell self-renewalimprovedin vitro Assayin vivoinnovationknockout animalmembernestin proteinreceptorsingle-cell RNA sequencingstemstem cell functionstem cells
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The phenotypic makeup and functional capacity of murine and human hematopoietic stem cells (HSC) has
been exhaustively investigated making HSC one of the most-characterized groups of cells in mammalian
biology. Still, not a single functional marker has been previously identified that is common to both murine and
human HSC while being also expressed on at least three important cellular components of the hematopoietic
niche (HN), namely osteoblasts (OB), endothelia cells (EC), and mesenchymal stem cells (MSC). Our focus on
CD166 began when we first established that CD166 identifies OB that mediate a hematopoiesis enhancing
activity. We also published that CD166 is expressed on normal murine and human HSC and plays a key role in
determining their functional capacity and the competence of the HN. We recently confirmed that CD166 is
expressed on a subset of EC and nestin+ MSC. Since CD166 is capable of mediating hetero- and homophilic
cell-cell interactions, we propose that CD166 serves as both ligand and receptor of HSC interactions with
cellular elements of the niche and is an important regulator of the competence of the HN and of stem
cell function. HSC from CD166-/- mice engraft poorly in lethally irradiated hosts. On the other hand CD166-/-
mice do not support the engraftment of LT-HSC suggesting that loss of CD166 abrogates the competence of
the HN. Marrow-homed LSK cells from wildtype (WT) donors lodged closer to the endosteum of host mice than
similar cells from knockout (KO) animals suggesting that engraftment is adversely impacted by the lack of
HSC-OB homophilic CD166-interactions7. Single-cell RNAseq analysis of WT and CD166-/- CD150+CD48- LSK
cells incubated with immobilized CD166 protein revealed that engagement of CD166 on these cells activated
cytokine signaling, epigenetic pathways, stem cell pluripotency genes, and mitochondria-related signaling
pathways. Based on these findings, we hypothesize that CD166 is a functional marker required for HSC-
niche interactions that support the competence of the hematopoietic niche. We also believe that
preferential CD166 homophilic interactions in the niche contribute to HSC regulation and maintenance
of the hematopoietic potential of stem cells. We will test these hypotheses by investigating 2 aims: 1) Test
the hypothesis that CD166 expression on OB, EC, and MSC in the hematopoietic niche is required for the
competence of the hematopoietic niche and 2) Test the hypothesis that hematopoietic stem cells lacking
CD166 homophilic interactions with OB, EC, and MSC in the niche fail to develop normally and acquire an
engraftment defect. The significance of this proposal is that it will examine the role of a new and unique
functional marker of human and murine HSC and will investigate the impact of CD166 modulation on stem cell
function. The novelty of this proposal stems from its potential to implicate CD166 in the regulation of the HN
and HSC that reside in and interact with CD166-rich cellular elements of this microenvironment. These studies
have the potential to define how homophilic CD166 interactions promote HSC self-renewal.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1097/moh.0000000000000656
发表时间:
2021-07-01
期刊:
Current opinion in hematology
影响因子:
3.2
作者:
[Ghosh J, Koussa RE, Mohamad SF, Liu J, Kacena MA, Srour EF]
通讯作者:
Srour EF
RR&D Research Career Scientist Award Application
-
批准号:10754152
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:Melissa A Kacena
-
依托单位:
"Novel therapeutic approaches to improve fracture healing while reducing pain behavior"
-
批准号:10609035
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:Melissa A Kacena
-
依托单位:
"Novel therapeutic approaches to improve fracture healing while reducing pain behavior"
-
批准号:10426446
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:Melissa A Kacena
-
依托单位:
Osteomacs and megakaryocytes interact to regulate hematopoietic stem cell function
-
批准号:10212373
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Angiogenic Therapy: Novel Approaches to Enhance Bone Regeneration in Aging - LOAD
-
批准号:10711847
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Osteomacs and megakaryocytes interact to regulate hematopoietic stem cell function
-
批准号:9764740
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Angiogenic Therapy: Novel Approaches to Enhance Bone Regeneration in Aging - AD/ADRD
-
批准号:10711880
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
ShEEP Request for a Kubtec XPERT 80 Shielded Cabinet X-ray System
-
批准号:9796215
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Angiogenic Therapy: Novel Approaches to Enhance Bone Regeneration in Aging
-
批准号:9757972
-
项目类别:
-
资助金额:$61.88万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Osteomacs and megakaryocytes interact to regulate hematopoietic stem cell function
-
批准号:10686056
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Angiogenic Therapy: Novel Approaches to Enhance Bone Regeneration in Aging
-
批准号:10356802
-
项目类别:
-
资助金额:$55.13万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Angiogenic Therapy: Novel Approaches to Enhance Bone Regeneration in Aging
-
批准号:10097960
-
项目类别:
-
资助金额:$56.37万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
CD166 Regulates Human and Murine Hematopoietic Stem Cell Function and the Hematopoietic Niche
-
批准号:10339403
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Angiogenic Therapy: Novel Approaches to Enhance Bone Regeneration in Aging
-
批准号:9900701
-
项目类别:
-
资助金额:$58.5万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Osteomacs and megakaryocytes interact to regulate hematopoietic stem cell function
-
批准号:10449234
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Osteomacs and megakaryocytes interact to regulate hematopoietic stem cell function
-
批准号:10017954
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Angiogenic Therapy: Novel Approaches to Enhance Bone Regeneration in Aging
-
批准号:10570206
-
项目类别:
-
资助金额:$55.13万
-
财政年份:2019
-
负责人:Melissa A Kacena
-
依托单位:
Impact of TPO Treatment on Bone Healing and Angiogenesis in Type 2 Diabetes
-
批准号:10383641
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Melissa A Kacena
-
依托单位:
Impact of TPO Treatment on Bone Healing and Angiogenesis in Type 2 Diabetes
-
批准号:9492356
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Melissa A Kacena
-
依托单位:
CD166 Regulates Human and Murine Hematopoietic Stem Cell Function and the Hematopoietic Niche
-
批准号:9126154
-
项目类别:
-
资助金额:$12.48万
-
财政年份:2015
-
负责人:Melissa A Kacena
-
依托单位:
海外基金